TrialNephron2020

A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.

Tadao Akizawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.